Description
Heart in Diabetes 8th Annual Heart in Diabetes Conference 2024
Heart in Diabetes
Include: 44 videos, size: 11.3 GB
Heart in Diabetes 8th Annual Heart in Diabetes (HiD) CME Conference is organized by The Metabolic Institute of America (TMIOA) and will be held from Jun 07 – 09, 2024 at Hilton Philadelphia at Penn’s Landing, Philadelphia, Pennsylvania, United States of America.
Heart in Diabetes
Learning Objectives:
Upon completion of this meeting, participants should be able to:
• Evaluate the extent of vascular disease in diabetes, obesity, and cardiometabolic syndrome.
• Be able to assess cardiovascular risk in diabetes.
• Describe the different etiologies of cardiomyopathies.
• Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia as well as hyperglycemia.
• Describe optimal use of technology—specifically CGM—and digital technology and their impact on diabetes and CVD
• Be able to recognize and manage hypoglycemia and its impact on comorbidities
• Evaluate stroke in diabetes and cardiorenal metabolic disease
• Be able to evaluate prevent and manage atherosclerosis and ASCVD
• Recognize the full spectrum of Heart Failure dictating approach to management
• Know GDMT in the 4 Pillar management of HFrEF
• Develop contemporary management of HFpEF
• Discuss the impact of obesity and diets on fatty liver, CKD, CVD, and HF
• Evaluate the evidence supporting the use of GLP1-RAs, SGLT inhibitors, nonsteroidal MRAs, and other treatments to reduce CKD, HF, and cardiovascular disease and mortality in patients with T2D
• Describe new and evolving agents in dyslipidemia treatment and how they can be used to reduce ASCVD
• Explain the important role of Lp(a) in the development atherosclerosis
• Understand the potential role and impact of AHA Presidential Advisory on Cardio-Kidney-Metabolic Health
• Discuss the changes in diagnosis and management based on DCRM 2.0 Global Multispecialty Practice Recommendations
• Evaluate the impact on clinical practice of new CVOTs, including those evaluating antihyperglycemic, lipid-lowering, and other medications such as nonsteroidal MRAs and anticoagulation therapies
• Understand the role of GLP1-RAs in prevention of CVD, strokes, and CKD in diabetes and obesity
• Describe the state of heart disease in women
• Discuss diabetes, CKD, CVD, and HF in diverse populations
• Develop treatment plans to prevent and manage CKD and its complications with ACE/ARB, SGLT inhibitors, finerenone, and GLP1-RAs in combination.
Heart in Diabetes
TARGET AUDIENCE
Heart in Diabetes
Pharmacist, Physician Assistant, Diabetologists, Cardiologists, Family Physicians, Nephrologists, Residents, Nurses, Internist, Dietitian, Medical Students, Endocrinologist, Nurse Practitioners, Fellows, Other health Professionals
SPECIALITIES
Endocrinology, Metabolism and Diabetes, Cardiology
Heart in Diabetes
Topics:
- AHA CKM Health Initiative The Nephrology Perspective.mp4
An Overview of Cardiovascular-Kidney-Metabolic (CKM) Health.mp4
Atherothrombotic Risk Stratification in Patients With Type 2 Diabetes.mp4
Beyond 10-Year Risk New Paradigms for Long-Term Risk Estimation With AHA PREVENT.mp4
Cardiovascular Disease in the Very Old.mp4
Cardiovascular Outcomes in GRADE – The Impact of Antihyperglycemic Agents in Lower Risk Patients With Type 2 Diabetes.mp4
Clinical Interventions in Atherosclerosis.mp4
CRM in Amyloidosis.mp4
Diabetic Foot Ulcers in the Cardiovascular Patient Population An AHA Scientific Statement.mp4
Eradicating Atherosclerotic Events by Targeting Early Subclinical Disease.mp4
Estimated Lifetime Benefits of SGLT2i, GLP-1RA, and Non-Steroidal MRAs in People With Type 2 Diabetes and Albuminuria.mp4
Exercise in Diabetes Care – From CV Outcomes to Longevity.mp4
FLOW – The First Dedicated CKD Outcomes Trial With a GLP-1 Receptor Agonist.mp4
Functional Hypothalamic Amenorrhea Consequences Beyond the Menstrual Cycle.mp4
Gestational Diabetes and Future Cardiovascular Disease in Women.mp4
GLP1-RA and Risk of Stroke.mp4
Guideline Recommended Therapy in Patients With Diabetic Kidney Disease.mp4
HDL-C Helpful, Harmful, Hopeful, or Guilty by Association.mp4
Heart Failure Post Myocardial Infraction and Valvular Disease.mp4
Hypertension and Hyperglycemia Twin Sisters Masquerading as Cushing Syndrome.mp4
Hypertension Awakenings Finally Something New to Talk About.mp4
Impact of Cumulative Risk Factor Exposure on Incident Cardiovascular Disease.mp4
Integrating Wearables, Behavior and AI to Improve Metabolic Health.mp4
Ketone Metabolism and the Human Heart Implications for Heart Failure.mp4
Lp(a) in ASCVD – What We Know, Should Know and Want to Know.mp4
Medical Treatment of Hypercortisolism With Relacorilant Final Results of the Phase 3 GRACE Study.mp4
Metabolic Dysfunction Associated Steatohepatitis Advancing the Understanding of Underlying Mechanisms, Diagnostic Approach and Therapeutic Strategies.mp4
Modifying Cardiovascular Risk Associated With CKD in T2D With Finerenone.mp4
New Emerging Treatment for DKD.mp4
New Targets and Upcoming Medications for Dyslipidemia.mp4
Optimal Strategy for HF Screening Among Adults With Diabetes Without ASCVD A Pooled Cohort Analysis.mp4
Outcome of Advanced CKD Without Albuminuria Impact of SGLT2i and GLP-1 RA.mp4
Predicting and Preventing Hospital Admissions in Patients With Heart Failure It’s Really Difficult.mp4
SELECT GLP1 RA Impact on ASCVD in Obesity Without Diabetes.mp4
Simultaneous vs. Sequential Start of Foundation Therapies in CKD.mp4
Social Isolation, Loneliness, and Diabetes.mp4
Stroke vs. CAD Disparities in Risk Factor Management.mp4
Technology in the Management of Diabetes.mp4
The Contemporary Management of Heart Failure.mp4
The Different Etiologies of Cardiomyopathy.mp4
The Dynamic Duo GLP-1 Receptor Agonists and SGLT2 Inhibitors.mp4
The Multiplying Effect of T2D With CKD on the Spectrum of Heart Disease and Mortality.mp4
The Proper Management of a Patient With Heart Failure Circa 2024.mp4
When Weight is a Barrier to Transplant Managing Obesity in Patients With Advanced HF.mp4
